A possible role of rifampicin in prolonging remission duration in acute myelogenous leukaemia.
The remission duration (RD) of 22 adult acute myelogenous leukaemia patients who received maintenance rifampicin treatment during 24 episodes was significantly longer than RD in 29 complete remission patients who received conventional maintenance chemotherapy (25 versus 9 months, p less than 0.003). Although this study was not randomized, the observed RD in the rifampicin group suggests a suppressive activity upon regrowth of residual disease in acute myelogenous leukaemia during apparent complete remission.
D002986:Clinical Trials as Topic; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D011379:Prognosis; D011897:Random Allocation; D012293:Rifampin / Q000627:therapeutic use*
D012293:Rifampin